Travere Therapeutics
TVTX
134 hedge funds and large institutions have $945M invested in Travere Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 49 reducing their positions, and 28 closing their positions.
89% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $1.26M
3.32% less ownership
Funds ownership: 105.56% → 102.24% (-3.3%)
8% less capital invested
Capital invested by funds: $1.03B → $945M (-$85.1M)
9% less funds holding
Funds holding: 147 → 134 (-13)
12% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 49
43% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 28
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$14.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.36M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$5.35M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$8.82M |
| 2 |
Millennium Management
New York
|
-$6.49M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5.9M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.1M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Parallax Volatility Advisers
San Francisco,
California
| – | -$408K | -19,999 | Closed |
|
152
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$330K | -16,181 | Closed |
|
|
AI
153
ArchPoint Investors
Coral Gables,
Florida
| – | -$303K | -14,863 | Closed |
|
154
HSBC Holdings
London,
United Kingdom
| – | -$254K | -12,453 | Closed |
|
|
BBVA
155
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
| – | -$204K | -10,000 | Closed |
|
|
AIM
156
Aigen Investment Management
New York
| – | -$204K | -9,992 | Closed |
|
157
Acadian Asset Management
Boston,
Massachusetts
| – | -$198K | -9,674 | Closed |
|
|
SO
158
STRS Ohio
Columbus,
Ohio
| – | -$93K | -4,600 | Closed |
|
159
Simplex Trading
Chicago,
Illinois
| – | -$24K | -1,236 | Closed |
|
|
CAN
160
Cetera Advisor Networks
El Segundo,
California
| – | -$20K | -1,000 | Closed |
|
|
QI
161
QS Investors
New York
| – | -$7K | -337 | Closed |
|
162
UBS Group
Zurich,
Switzerland
| – | -$5K | -237 | Closed |
|
TVTX Hedge Fund Activity: Q3 2020 in Review
134 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2020, worth a combined $945M — down 8.3% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of TVTX and 16 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 43 added.
The largest buyer was Janus Henderson Group, adding an estimated $14.5M. The largest seller was Scopia Capital Management, cutting an estimated $8.82M.
- 134 institutional investors held Travere Therapeutics (TVTX) as of Q3 2020, down from 147 in Q2 2020.
- Funds reported $945M of Travere Therapeutics stock for Q3 2020, down 8.3% quarter-over-quarter.
- 16 funds opened new Travere Therapeutics positions in Q3 2020 and 28 closed out, a net change of -12 holders.
- The largest Travere Therapeutics buyer in Q3 2020 was Janus Henderson Group, an estimated $14.5M added.
- The largest Travere Therapeutics seller in Q3 2020 was Scopia Capital Management, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2020.